Leuprolide
Also known as: Lupron, Leuprorelin, TAP-144
Leuprolide is a synthetic gonadotropin-releasing hormone (GnRH) agonist that suppresses testosterone and estrogen production through pituitary desensitization. Research applications include prostate cancer studies, endometriosis models, and fertility research protocols.
Leuprolide is a 1209.4 Da research peptide. Leuprolide is a synthetic gonadotropin-releasing hormone (GnRH) agonist that suppresses testosterone and estrogen production through pituitary desensitization. Research applications include prostate cancer studies, endometriosis models, and fertility research protocols.
Also called: Lupron, Leuprorelin, TAP-144
1209.4
Molecular Weight
Daltons
2
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
1-7.5
Typical Dose
mg
Overview
Leuprolide functions as a potent GnRH receptor agonist that initially stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release before causing receptor desensitization and downregulation. This biphasic response leads to profound suppression of gonadal hormone production within 2-4 weeks of treatment initiation. The peptide demonstrates high binding affinity for GnRH receptors and extended half-life compared to endogenous GnRH. Research protocols utilize leuprolide for creating hormone-depleted models in oncology studies, investigating reproductive physiology, and examining sex hormone-dependent processes. The compound's ability to create reversible medical castration makes it valuable for studying androgen-dependent and estrogen-dependent biological mechanisms.
Key Takeaways: Leuprolide
- Strongest evidence supports Leuprolide for hormone suppression for cancer research and reproductive physiology studies
- Research doses typically range from 1 to 7.5 mg via subcutaneous
- 2 benefits with strong evidence, 3 moderate, 1 preliminary
- Half-life: 3-4 hours
- 4 cited research studies in this guide
Mechanism of Action
Leuprolide binds to GnRH receptors in the anterior pituitary with high affinity, initially triggering LH and FSH release. Continuous exposure leads to receptor desensitization and downregulation, resulting in suppressed gonadotropin secretion. This cascade effect dramatically reduces testosterone production in males and estrogen/progesterone synthesis in females. The peptide resists enzymatic degradation due to D-amino acid substitutions, extending its biological activity compared to native GnRH.
Research Benefits
Leuprolide at a Glance
Leuprolide binds to GnRH receptors in the anterior pituitary with high affinity, initially triggering LH and FSH release.
Hormone Suppression for Cancer Research
Strong EvidenceCreates reliable androgen-depleted and estrogen-depleted research models by suppressing gonadal hormone production to castrate levels within 28 days
Reproductive Physiology Studies
Strong EvidenceEnables investigation of sex hormone-dependent processes and reproductive cycle regulation through reversible gonadal suppression
Endometriosis Research Models
Moderate EvidenceProvides consistent estrogen suppression for studying endometrial tissue growth patterns and inflammatory responses
Fertility Research Applications
Moderate EvidenceSupports controlled ovarian stimulation protocols and timing synchronization in reproductive studies
Precocious Puberty Research
Moderate EvidenceAllows investigation of early pubertal development mechanisms through GnRH axis suppression
Bone Density Studies
PreliminaryCreates hormone-deficient models for examining bone metabolism and osteoporosis development pathways
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Hormone suppression research | 1–7.5 mg | subcutaneous |
| Cancer research models | 3.75–22.5 mg | intramuscular |
| Reproductive studies | 0.5–3.75 mg | subcutaneous |
Frequency
Monthly depot injections or daily subcutaneous administration
Timing
Consistent timing for depot formulations; morning administration for daily protocols
Cycle Length
Treatment duration varies by research protocol: 1-6 months typical
Research Notes
- 1Initial hormone surge occurs during first 1-2 weeks before suppression
- 2Depot formulations provide sustained release over 1-3 months
- 3Monitor for breakthrough hormone production in long-term studies
- 4Reconstitute powder immediately before injection
Reconstitution Guide
Standard Reconstitution
Vial Size
5 mg
Bacteriostatic Water
1 mL
Concentration
50 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Leuprolide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 1 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C refrigerated. 24 hours after reconstitution.
Storage Temperature
2-8°C refrigerated
Shelf Life
24 hours after reconstitution
Important Notes
- •Use sterile bacteriostatic water for reconstitution
- •Swirl gently to dissolve, do not shake vigorously
- •Solution should be clear and colorless
- •Single-use vials only, discard after use
Leuprolide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Leuprolide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Hot flashes and vasomotor symptoms
- !Decreased bone mineral density
- !Reduced muscle mass and strength
- !Mood changes and depression
- !Decreased libido
- !Injection site reactions
- !Headache and dizziness
- !Fatigue and weakness
- !Joint pain and stiffness
- !Sleep disturbances
Potential Interactions
- ⚡Anticoagulants may have altered effects due to hormonal changes
- ⚡Diabetes medications may require adjustment due to metabolic changes
- ⚡Bone-sparing agents interaction with bone metabolism effects
- ⚡Cardiovascular medications due to lipid profile changes
- ⚡Antidepressants for mood-related side effects management
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Long-term effects of leuprolide acetate depot on bone mineral density
Demonstrated significant bone density reduction with leuprolide treatment, establishing bone loss patterns during GnRH suppression therapy
Leuprolide acetate depot in the treatment of endometriosis: a randomized, placebo-controlled, multicenter study
Multicenter trial showing efficacy of leuprolide in endometriosis treatment with detailed side effect profile documentation
Hormonal and metabolic effects of polyestradiol phosphate and leuprolide acetate in patients with prostatic carcinoma
Comparative study examining testosterone suppression patterns and metabolic consequences of leuprolide treatment in prostate cancer research
Central precocious puberty: treatment with a long-acting analogue of luteinizing hormone-releasing hormone
Early clinical research establishing leuprolide's effectiveness in suppressing precocious puberty through GnRH axis modulation
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Leuprolide typically achieves castrate levels of testosterone (below 50 ng/dL) or menopausal estrogen levels within 2-4 weeks. Initial hormone surge occurs during the first 7-14 days before suppression begins.
Daily leuprolide requires subcutaneous injection every 24 hours while depot formulations provide sustained release over 1-6 months through intramuscular injection. Depot forms offer better compliance but less dosing flexibility.
Yes, hormone suppression is reversible. Testosterone and estrogen levels typically recover to baseline within 3-12 months after discontinuing treatment, with younger subjects recovering faster than older ones.
Most side effects resolve after treatment cessation, but prolonged use may cause lasting bone density reduction. Some metabolic changes and mood effects can persist for months after discontinuation.
Store lyophilized leuprolide at 2-8°C refrigerated. Protect from light and moisture. Depot formulations should remain at room temperature before injection but refrigerate if storing long-term.
Monitor hormone levels (LH, FSH, testosterone/estradiol), bone density markers, lipid profiles, and metabolic parameters. Check injection sites for reactions and assess mood changes regularly.
Leuprolide can alter the metabolism and effectiveness of compounds that depend on sex hormone levels. Always consider hormonal status changes when designing combination research protocols.
Use sterile technique with proper needle size for route. Rotate injection sites to prevent tissue damage. For depot injections, use deep intramuscular technique in gluteal muscle with Z-track method.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.